Trials / Completed
CompletedNCT03587194
Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis
A Single Center Study to Evaluate the Effectiveness and Safety of Add on Enstilar® in Patients Using OTEZLA® for Moderate to Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Psoriasis Treatment Center of Central New Jersey · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Add-on Enstilar to Otezla therapy.
Detailed description
50 adult patients with moderate to severe plaque psoriasis will be given OTEZLA® for 16 weeks with add-on Enstilar.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Otezla | Otezla 30mg BID |
Timeline
- Start date
- 2018-07-23
- Primary completion
- 2019-07-01
- Completion
- 2019-07-01
- First posted
- 2018-07-16
- Last updated
- 2024-04-16
- Results posted
- 2024-04-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03587194. Inclusion in this directory is not an endorsement.